SOUTH SAN FRANCISCO, CA -- 11/03/09 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its Executive team are scheduled to
present at the following four upcoming healthcare conferences throughout
the month of November:
Merriman Curhan Ford's 6th Annual Investor Summit 2009
Date: Tuesday, November 10, 2009
Time: 11:20 a.m. Eastern Time
Location: Hotel Sofitel, New York, New York
Presenter: Robert I. Blum, President and Chief Executive Officer
Canaccord Adams' 3rd Annual Cardiovascular Conference
Date: Tuesday, November 10, 2009
Time: 2:30 p.m. Pacific Time
Location: Nikko Hotel, San Francisco, California
Presenters: Sharon A. Barbari, EVP Finance and Chief Financial Officer
Andrew A. Wolff, M.D., SVP Clinical Research and Chief Medical
Officer
2009 Credit Suisse Healthcare Conference
Date: Wednesday, November 11, 2009
Time: 4:30 p.m. Mountain Time
Location: Arizona Biltmore Hotel, Phoenix, Arizona
Presenter: Robert I. Blum, President and Chief Executive Officer
Lazard Capital Markets' 6th Annual Healthcare Conference
Date: Tuesday, November 17, 2009
Time: 11:30 a.m. Eastern Time
Location: The St. Regis Hotel, New York, New York
Presenter: Robert I. Blum, President and Chief Executive Officer
Interested parties may access the live audio webcast of these presentations
and replays by visiting the Investor Relations section of the Cytokinetics
website at www.cytokinetics.com. The webcast replay of these presentations
will be archived on the Presentations page within the Investor Relations
section of Cytokinetics' website for two weeks following the completion of
the event.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil (formerly CK-1827452), is in
Phase II clinical development for the potential treatment of heart failure.
Amgen Inc. holds an exclusive license worldwide (excluding Japan) to
develop and commercialize omecamtiv mecarbil and related compounds, subject
to Cytokinetics' specified development and commercialization participation
rights. Cytokinetics is independently developing CK-2017357, a skeletal
muscle activator, as a potential treatment for diseases and conditions
associated with aging, muscle wasting or neuromuscular dysfunction.
CK-2017357 is in Phase I clinical development. Cytokinetics is also
conducting non-clinical development of compounds that inhibit smooth muscle
contractility and which may be useful as potential treatments for diseases
and conditions such as systemic hypertension, pulmonary arterial
hypertension or bronchoconstriction. In addition, prior Cytokinetics'
research generated three anti-cancer drug candidates in Phase I clinical
development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a
partner for ispinesib and SB-743921 and GSK-923295 is being developed under
Cytokinetics' collaboration with GlaxoSmithKline. All of these drug
candidates and potential drug candidates have arisen from Cytokinetics'
research activities and are directed towards the cytoskeleton. The
cytoskeleton is a complex biological infrastructure that plays a
fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to planned presentations and the
properties and potential benefits of Cytokinetics' drug candidates and
potential drug candidates. Such statements are based on management's
current expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory approval and
production of Cytokinetics' drug candidates and potential drug candidates
that could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results, Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy and
Cytokinetics may be unable to obtain the additional funding necessary to
advance some or all of its research and development programs. For further
information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the
Securities and Exchange Commission.
Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan
Director, Investor and Media Relations
(650) 624-3000
